• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

意大利政府在药品发现、开发和获取方面的政策。

On the Policy of the Italian Government in the Discovery, Development, and Access to Medicines.

机构信息

Department of Experimental Medicine - Section of Pharmacology "L. Donatelli", University of Campania "Luigi Vanvitelli", Napoli, Italy.

Department of Biomedical and Clinical Sciences, L. Sacco University Hospital, Università degli Studi di Milano, Milano, Italy.

出版信息

Clin Ther. 2018 Nov;40(11):1931-1940. doi: 10.1016/j.clinthera.2018.09.015. Epub 2018 Oct 27.

DOI:10.1016/j.clinthera.2018.09.015
PMID:30458933
Abstract

This commentary outlines how discovery, development, and access to medicines are regulated and promoted in Italy by the government through the Ministry of University and Research, the Ministry of Health, and the Italian Medicines Agency. We describe and comment on the existing research programs stimulating preclinical, translational, and clinical research and how access to medicines and their pricing is regulated by Italy's National Health Service both at the national and regional levels. Finally, we describe the current scenario of industrial research and medicines manufacturing. The resulting picture shows a country in which high-level competitive research on medicines is promoted alongside an excellent national health system working toward fairness of access to health care services for all citizens and fiscal solidarity as a fundamental form of system financing. Critical challenges still exist, including the relative scarcity of public funding for research and the non-uniform access to the benefits of the National Health Service across Italian regions.

摘要

本文概述了意大利政府如何通过大学和研究部、卫生部和意大利药品管理局对药品的发现、开发和获取进行监管和促进。我们描述并评论了现有的研究计划,这些计划刺激了临床前、转化和临床研究,以及意大利国家卫生服务系统如何在国家和地区层面上监管药品的可及性及其定价。最后,我们描述了当前的工业研究和药品制造情况。由此可见,意大利在促进高水平的药品竞争研究的同时,拥有一个优秀的国家卫生系统,致力于为所有公民提供公平的医疗服务,并将财政团结作为系统融资的基本形式。仍然存在一些关键挑战,包括研究公共资金相对匮乏,以及意大利各地区获得国家卫生服务福利的机会不均等。

相似文献

1
On the Policy of the Italian Government in the Discovery, Development, and Access to Medicines.意大利政府在药品发现、开发和获取方面的政策。
Clin Ther. 2018 Nov;40(11):1931-1940. doi: 10.1016/j.clinthera.2018.09.015. Epub 2018 Oct 27.
2
Veneto Region, Italy. Health system review.意大利威尼托大区。卫生系统评估。
Health Syst Transit. 2012;14(1):i-xix, 1-138.
3
The healthcare system and the provision of oral healthcare in European Union member states. Part 8: Italy.欧盟成员国的医疗保健系统及口腔医疗保健服务。第8部分:意大利。
Br Dent J. 2017 May 26;222(10):809-817. doi: 10.1038/sj.bdj.2017.459.
4
Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.两国患者获取药品情况比较:卫生体制相似,药品政策不同——基于全面文献回顾的结果
Res Social Adm Pharm. 2019 Mar;15(3):231-243. doi: 10.1016/j.sapharm.2018.04.006. Epub 2018 Apr 13.
5
Fiscal decentralization in the Italian NHS: what happens to interregional redistribution?意大利国民医疗保健体系中的财政分权:区域间再分配会发生什么变化?
Health Policy. 2011 Apr;100(1):71-80. doi: 10.1016/j.healthpol.2010.08.016. Epub 2010 Sep 22.
6
Government review aims to speed up NHS access to new medicines.政府审查旨在加快英国国家医疗服务体系获取新药的速度。
BMJ. 2014 Nov 23;349:g7090. doi: 10.1136/bmj.g7090.
7
Provision of pharmaceuticals in Australian hospitals: equity of access?澳大利亚医院的药品供应:获取公平性如何?
Pharm World Sci. 2007 Apr;29(2):47-50. doi: 10.1007/s11096-006-9066-y. Epub 2006 Dec 6.
8
[Analysis and reflections on the 2019 initiative that reforms Mexico's Ley General de Salud].[对2019年墨西哥《健康总法》改革倡议的分析与思考]
Salud Publica Mex. 2019 Sep-Oct;61(5):685-691. doi: 10.21149/10894.
9
Powerful Ideas for Global Access to Medicines.关于全球药品可及性的有力观点。
N Engl J Med. 2017 Feb 9;376(6):505-507. doi: 10.1056/NEJMp1613861. Epub 2017 Jan 18.
10
The "Essential Levels of Care" in Italy: when being explicit serves the devolution of powers.意大利的“基本护理级别”:明确规定何时有助于权力下放。
Eur J Health Econ. 2005 Dec;Suppl(Suppl 1):46-52. doi: 10.1007/s10198-005-0318-x.

引用本文的文献

1
Pharmacovigilance study on the reporting frequency of atrial fibrillation with immune checkpoint inhibitors: insights from FDA Adverse Event Reporting System.免疫检查点抑制剂所致心房颤动报告频率的药物警戒研究:来自美国食品药品监督管理局不良事件报告系统的见解
Ther Adv Drug Saf. 2025 Apr 21;16:20420986241312497. doi: 10.1177/20420986241312497. eCollection 2025.
2
Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database.对脊髓性肌萎缩症患者中与onasemnogene abeparvovec(Zolgensma)相关的不良事件的综合分析:来自FAERS数据库的见解
Front Pharmacol. 2025 Jan 7;15:1475884. doi: 10.3389/fphar.2024.1475884. eCollection 2024.
3
Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System.
用于脊髓性肌萎缩症罕见病的孤儿药onasemnogene abeparvovec(Zolgensma)的真实世界安全性数据:一项基于欧洲药品管理局不良事件报告系统的药物警戒研究。
Pharmaceuticals (Basel). 2024 Mar 19;17(3):394. doi: 10.3390/ph17030394.
4
Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years.免疫检查点抑制剂之间的周围神经病变是否存在差异?来自欧洲上市后监测数据库的过去10年报告。
Front Immunol. 2023 Mar 16;14:1134436. doi: 10.3389/fimmu.2023.1134436. eCollection 2023.
5
The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs.临床研究中的新范式:从早期准入计划到满足未满足医疗需求的新型治疗方法。
Front Pharmacol. 2019 Feb 13;10:111. doi: 10.3389/fphar.2019.00111. eCollection 2019.